09.07.23
Microbot Medical Inc. has completed an extended pre-clinical study held by key opinion leaders at a New York-based research lab.
An interventional radiology team utilized the system and performed dozens of catheterizations, including the utilization of the system’s remote operation capabilities, to pre-determined vascular targets, with a 100% success rate of reaching the intended target with no observable on-site complications. It was the first study in which the company allowed participants of leading medical industry organizations to join.
Similar to previous studies, Microbot Medical received positive real-time user feedback, with respect to the system's intuitiveness, ease of set up and use, and value added, with participants noting the ability to control procedures remotely via the LIBERTY Robotic Surgical System’s remote controller. Moreover, the company received valuable input from the industry participants, which aligned to the value proposition LIBERTY is expected to bring to the market and which will assist in the LIBERTY's future adoption when commercialized.
The LIBERTY Robotic Surgical System aims to improve the way surgical robotics is being used in endovascular procedures by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain.
"We continue to expand our close relationships with international KOLs and, for the first time, we incorporated executives from the medical industry. We believe that our LIBERTY Robotic Surgical System has the potential to benefit patients, physicians and commercial organizations from the medical field as we continue to advance in the regulatory process with the FDA and other regions across the world. Following several successful studies in Europe, and now in the US, the support and endorsement we receive has great value for our future commercial plans," Microbot Medical CEO Harel Gadot said.
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the body's natural and artificial lumens.
An interventional radiology team utilized the system and performed dozens of catheterizations, including the utilization of the system’s remote operation capabilities, to pre-determined vascular targets, with a 100% success rate of reaching the intended target with no observable on-site complications. It was the first study in which the company allowed participants of leading medical industry organizations to join.
Similar to previous studies, Microbot Medical received positive real-time user feedback, with respect to the system's intuitiveness, ease of set up and use, and value added, with participants noting the ability to control procedures remotely via the LIBERTY Robotic Surgical System’s remote controller. Moreover, the company received valuable input from the industry participants, which aligned to the value proposition LIBERTY is expected to bring to the market and which will assist in the LIBERTY's future adoption when commercialized.
The LIBERTY Robotic Surgical System aims to improve the way surgical robotics is being used in endovascular procedures by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain.
"We continue to expand our close relationships with international KOLs and, for the first time, we incorporated executives from the medical industry. We believe that our LIBERTY Robotic Surgical System has the potential to benefit patients, physicians and commercial organizations from the medical field as we continue to advance in the regulatory process with the FDA and other regions across the world. Following several successful studies in Europe, and now in the US, the support and endorsement we receive has great value for our future commercial plans," Microbot Medical CEO Harel Gadot said.
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the body's natural and artificial lumens.